Archival

Quarterly Results

Q1 Jun 2017
Q2 Sep 2017
Standalone PDF 135KB
Q3 Dec 2017
Standalone PDF 124KB

Q1 Jun 2016
Standalone PDF 106KB
Q2 Sep 2016
Standalone PDF 115KB
Q3 Dec 2016

Q1 Jun 2015
Q2 Sep 2015
Q3 Dec 2015

Q1 Jun 2014
Standalone PDF 83 KB
Q2 Sep 2014
Standalone PDF 126KB
Q3 Dec 2014

Q1 Mar 2013
Standalone PDF 102KB
Q2 Jun 2013
Standalone PDF 102KB
Q3 Sep 2013
Standalone PDF 113KB
Q4 Dec 2013
Standalone PDF 125KB

Q1 Mar 2012
Q2 Jun 2012
Q3 Sep 2012

Q1 Mar 2011
Q2 Jun 2011
Q3 Sep 2011
Standalone PDF 216KB
Q1 Mar 2010
Q2 Jun 2010
Q3 Sep 2010
Q1 Mar 2007
Download PDF 50KB
Q2 Jun 2007
Download PDF 50KB
Q3 Sep 2007
Download PDF 50KB

Annual Results

Annual Result 2016-17
Consolidated
Download
PDF 164KB
Standalone
Download
PDF 118KB
Annual Result 2015-16
Consolidated
Download
PDF 95KB
Standalone
Download
PDF 119KB
Annual Result 2014-15
Consolidated
Download
PDF 136KB
Standalone
Download PDF 77KB
Annual Result 2013-14
Consolidated
Download
PDF 119KB
Standalone
Download PDF 134KB
Annual Result 2012
Consolidated
Download
PDF 135KB
Standalone
Download PDF 112KB
Annual Result 2011
Consolidated
Download
PDF 89KB
Standalone
Download PDF 356KB
Annual Result 2010
Consolidated
Download
PDF 50KB
Standalone
Download PDF 50KB

Analyst Reports

Date Title Report
14 Nov 17 ICICI Securities Limited Report PDF 283 KB
01 Nov 17 HDFC Securities - Strides Shasun Q2 FY 18 PDF 404 KB
31 Oct 17 Macquarie Report - Strides Shasun Q2 FY 18 PDF 775 KB
31 Oct 17 IDFC Securities - Strides Shasun Q2 FY 18 PDF 332 KB
23 Oct 17 Macquarie Report – India Pharmaceuticals PDF 775 KB
16 Oct 17 HDFC Securities - Institutional Research Report PDF 998 KB
17 Aug 17 IDFC Securities – Strides Shasun Q1FY18 PDF 327 KB
14 Aug 17 Jefferies Strides Q1 FY 18 PDF 628 KB
14 Aug 17 Credit Suisse Strides 1QFY18 PDF 345 KB
12 Aug 17 Axis Capital- Strides Shasun Q1FY18 PDF 373 KB
11 Aug 17 Motilal Oswal Report PDF 339 KB
7 Aug 17 Strides Initiation Note - Motilal Oswal PDF 3.13 MB
Date Title Report
10 Dec 15 Credit Suisse 10 Dec 2015 PDF 1.66 MB
08 July 15 Macquarie Research 8 Jul 2015 PDF 5.16 MB
01 July 15 Axis capital analyst report 1 Jul 2015 PDF 1.12 MB
25 May 15 Antique stock broking analyst report Q4FY15 results update PDF 106 KB
25 May 15 Reliance analyst report Q4FY15 result update PDF 152 KB
25 May 15 Religare analyst report Q4FY15 results review PDF 254 KB
21 May 15 Religare analyst report update PDF 212 KB
Date Title Report
18 Mar 15 Religare Report on Strides PDF 395 KB
17 Dec 14 Strides Arcolab – Nirmal Bang Securities Coverage PDF 1.02 MB
4 Jul 14 Strides Arcolab – Antique broking July 2014 PDF 100 KB
23 May 14 Strides Arcolab Macquarie report May 2014 PDF 561 KB

Subsidiary Financials

Sl No Subsidiary Name Document
01 Altima Innovation, USA FY 17 1.10 MB
02 Arrow Pharma, Sri Lanka FY 17 118 KB
03 Arrow Pharma, Singapore FY 17 113 KB
04 Arrow Remedies, India FY 2017 1.10 MB
05 Arrow Pharma, Philppines FY 17 112 KB
06 Beltapharm, Italy FY 2016 1.98 MB
07 Chemsynth Laboratories, India FY17 953 KB
08 GP Canada Inc, FY 17 96 KB
09 GP International, Singapore FY 17 74 KB
10 GP, Malayasia FY 17 80 KB
11 GP, New Zealand FY 17 73 KB
12 GP SA, South Africa FY 17 72 KB
13 GP Holding, Australia FY 17 81 KB
14 GP Australia, FY 17 289 KB
15 GP UK Ltd, UK FY 17 102 KB
16 Pharmacy Alliance, Australia FY 17 274 KB
17 Shasun NBI LLC, USA FY 17 330 KB
18 Shasun Pharma Soluitions Inc, USA FY 17 233 KB
19 Shasun USA Inc, USA FY 17 332 KB
20 Solara Active Pharma, India FY 17 489 KB
21 Stabilis Pharma Inc, USA FY 17 275 KB
22 Stelis Biopharma, Malaysia FY 17 774 KB
23 Stelis Biopharma, India FY 17 175 KB
24 Strides Africa Ltd, Africa FY 17 82 KB
25 Strides Arcolab (Australia) Pty Ltd, Australia FY 17 8.27 MB
26 Strides Arcolab International, UK FY 17 94 KB
27 Strides CIS, FY 17 102 KB
28 Strides Emerging Markets, India FY 17 1.06 MB
29 Strides Healthcare, India FY 17 1.59 MB
30 Strides Pharma (Cyprus) Ltd, Cyprus FY 17 306 KB
31 Strides Pharma SA, South Africa FY 17 89 KB
32 Strides Pharma Global, UK FY 17 89 KB
33 Strides Pharma Global, Singapore FY 17 314 KB
34 Strides Pharma Inc, USA FY 17 275 KB
35 Strides Pharma International, Cyprus FY 17 97 KB
36 Strides Pharma Ltd, Cyprus FY 17 213 KB
37 Strides Pharma UK, FY 17 2.96 MB
38 Strides Specialties (Holdings), Mauritius FY 17 12 KB
39 SVADS Holdings, Switzerland FY 17 2.92 MB
40 Universal Corporation, Kenya FY 16 1.76 MB
41 Fagris, India FY 17 248 KB
Sl No Subsidiary Name Document
01 Alliance Pharmacy Pty Ltd Australia 157 KB
02 Altima USA 35 KB
03 APHAD Cameroon 1.30 MB
04 Arrow Pharmaceuticals Australia 1.06 MB
05 Arrow Pharma Life Inc Philippines 163 KB
06 Arrow Pharma Pte Ltd Singapore 162 KB
07 Arrow Pharma Pvt Ltd Srilanka 164 KB
08 Arrow Remedies India 682 KB
09 Beltapharm SPA Italy 1.28 MB
10 Chemsynth Laboratories India 744 KB
11 Fagris Medica India 1.34 MB
12 Pharmacy Alliance Group Holdings Australia 33 KB
13 Pharmacy Alliance Investments Australia 32 KB
14 Pharmacy Alliance Pty Ltd Australia 164 KB
15 SAIL UK 960 KB
16 Shasun NBI Financials FY 2016.pdf 476 KB
17 Shasun Pharma Inc. USA 243 KB
18 Shasun Pharma Solution UK 10.6 MB
19 Shasun USA Inc. USA 448 KB
20 Sorepharm SA Burkino Faso 36KB
21 SPC Co. Ltd Sudan 34 KB
22 SPIL Cyprus 846 KB
23 SSHL Mauritius 36 KB
24 Stabilis Pharma Inc. USA 324 KB
25 Stelis Biopharma India 1.53 MB
26 Stelis Biopharma Malaysia 1.12 MB
27 Strides Pharma Ltd Cyprus 68 KB
28 Strides Africa Ltd BVI 18 KB
29 Strides Arcolab Australia 772 KB
30 Strides Biologix India 1.03 MB
31 Strides CIS Cyprus 36 KB
32 Strides Emerging Markets India 886 KB
33 Strides Healthcare ndia 714 KB
34 Strides Pharma Global Singapore 1.25 MB
35 Strides Pharma Inc USA 1.24 MB
36 Strides Pharma Botswana 35 KB
37 Strides Pharma Cameroon 34 KB
38 Strides Pharma (Cyprus) Ltd Cyprus 1.19 MB
39 Strides Pharma Mozambique 34 KB
40 Strides Pharma Namibia 35 KB
41 Strides Pharma (SA) Pty Ltd South Africa 160 KB
42 Strides Pharma Singapore 976 KB
43 Strides Pharma UK 35 KB
44 Strides Shasun UK 1.04 MB
45 SVADS Holdings Switzerland 214 KB
46 SVNL Nigeria 1.30 MB
Sl No Subsidiary Name Document
01 African Pharmaceuticals Development Company, Cameroon 714 KB
02 Beltapharma SPA, Italy 775 KB
03 Co-Pharma Limited, UK 660 KB
04 Fagris FY-14-15 Financials 915 KB
05 Sorepharma, Burkisnofaso 544 KB
06 SPC Co. Limited, Sudan 618 KB
07 Stelis Biopharma (Malaysia) SDN BHD, Malaysia 521 KB
08 Stelis Biopharma Pvt. Ltd., India 1.31MB
09 Strides Africa Limited, BVI 517 KB
10 Strides Arcolab International Limited, UK 549 KB
11 Strides CIS Limited, Cyprus 505 KB
12 Strides Emerging Market Pvt. Ltd. India 1.10MB
13 Strides Healthcare Pvt. Ltd. India 654 KB
14 Strides Pharma Asia Pte Limited, Singapore 485 KB
15 Strides Pharma Botswana (Pty) Limited, Botswana 461 KB
16 Strides Pharma Cameroon 548 KB
17 Strides Pharma Cyprus Limited, Cyprus 538 KB
18 Strides Pharma Global Pte Limited, Singapore 524 KB
19 Strides Pharma Inc, USA 182 KB
20 Strides Pharma International Limited, Cyprus 459 KB
21 Strides Pharma Limited, Cyprus 544 KB
22 Strides Pharma, Mozambique 490 KB
23 Strides Pharma Namibia 554 KB
24 Strides Pharmaceuticals (Holdings) Limited, Cyprus 530 KB
25 Strides Specialties (Holding) Limited, Mauritius 484 KB
26 Strides Vital Nigeria Limited, Nigeria 636 KB

Press Releases / Stock Exchange Intimation

Date Title   Report

31 Dec 2017 Shareholding Pattern Shareholding Pattern PDF 906 KB
28 Dec 2017 Strides Shasun approval for composite scheme Strides Shasun approval for composite scheme PDF 2 MB
20 Dec 2017 Acquisition of Trinity Pharma Acquisition of Trinity Pharma PDF 239 KB
04 Dec 2017 Update on ‘Divestment of India brand business to Eris Lifesciences’ Update on ‘Divestment of India brand business to Eris Lifesciences’ PDF 185 KB
22 Nov 2017 USFDA Approval for Acetazolamide Tablets USFDA Approval for Acetazolamide Tablets PDF 78 KB
18 Nov 2017 Strides Shasun divests India brand business to Eris Lifesciences Strides Shasun divests India brand business to Eris Lifesciences PDF 625 KB
31 Oct 2017 Press Release – Q2 FY 18 Press Release – Q2 FY 18 PDF 242 KB
31 Oct 2017 SSL_Consol Q2 FY 18 Financials SSL_Consol Q2 FY 18 Financials PDF 307 KB
31 Oct 2017 SSL_Standalone Q2 FY 18 Financials SSL_Standalone Q2 FY 18 Financials PDF 135 KB
31 Oct 2017 Strides Shasun Stock Exchange Intimation Post Meeting Strides Shasun Stock Exchange Intimation Post Meeting PDF 1 MB
31 Oct 2017 SSL - Intimation to SE on Meger of WoS SSL - Intimation to SE on Meger of WoS PDF 239 KB
31 Oct 2017 Letter to SE_Allotment of shares under ESOP 2015 Letter to SE_Allotment of shares under ESOP 2015 PDF 44 KB
30 Oct 2017 SSL Earnings Call Intimation SSL Earnings Call Intimation PDF 45 KB
27 Oct 2017 Strides Shasun SE Intimation Strides Shasun SE Intimation PDF 42 KB
25 Oct 2017 Strides Shasun Announcement of Board Meeting Strides Shasun Announcement of Board Meeting PDF 44 KB
30 Sep 2017 Shareholding Pattern Shareholding Pattern 30 September 2017 PDF 3 MB
20 Sep 2017 USFDA Approval for Omega-3-Acid Ethyl Esters capsules USFDA Approval for Omega-3-Acid Ethyl Esters capsules PDF 55 KB
15 Sep 2017 Outcome of 26 th AGM - Disclosure under SEBI LODR Outcome of 26<sup>th</sup> AGM - Disclosure under SEBI LODR PDF 289 KB
15 Sep 2017 Voting Results and Scrutinizer Report of 26 th AGM Voting Results and Scrutinizer Report of 26<sup>th</sup> AGM PDF 1.23 MB
12 Sep 2017 USFDA Approval for Potassium Citrate Extended-Release Tablets USFDA Approval for Potassium Citrate Extended-Release Tablets PDF 60 KB
01 Sep 2017 EIR from US FDA on continued GMP status for flagship KRSG facility in Bangalore. EIR from US FDA on continued GMP status for flagship KRSG facility in Bangalore PDF 40 KB
31 Aug 2017 Arrow Pharmaceuticals acquires Amneal Pharmaceuticals in Australia Arrow Pharmaceuticals acquires Amneal Pharmaceuticals in Australia PDF 58 KB
31 Aug 2017 Intimation in newspaper advertisement on AGM notice Intimation in newspaper advertisement on AGM notice PDF 445 KB
24 Aug 2017 Notice of 26 th AGM Notice of 26<sup>th</sup> AGM PDF 1.36 MB
11 Aug 2017 SSL_Consol Q1 FY 18 Financials SSL_Consol Q1 FY 18 Financials PDF 107 KB
11 Aug 2017 SSL Standalone Q1 FY 18 Financials. SSL Standalone Q1 FY 18 Financials PDF 92 KB
11 Aug 2017 Press Release – Q1 FY 18 Press Release – Q1 FY 18 PDF 160 KB
24 July 2017 USFDA Approval for Cetirizine Softgel Capsules USFDA Approval for Cetirizine Softgel Capsules PDF 56.3 KB
03 July 2017 USFDA Approval for Promethazine HCL Tablets USFDA Approval for Promethazine HCL Tablets PDF 74.5 KB
30 June 2017 SSL Shareholding Pattern SSL Shareholding Pattern PDF 720 KB
30 June 2017 CCI Approval for the Scheme CCI Approval for the Scheme PDF 40.1 KB
22 June 2017 Update on transaction - Vivimed Labs Update on transaction - Vivimed Labs PDF 32.7 KB
12 June 2017 Clarification on Article appeared in online edition of Mint Clarification on Article appeared in online edition of Mint PDF 34.3 KB
12 June 2017 Analyst investors meet schedule Analyst investors meet schedule PDF 60.4 KB
12 June 2017 USFDA Approval for Amantadine Hydrochloride Tablets USFDA Approval for Amantadine Hydrochloride Tablets PDF 51.6 KB
08 June 2017 USFDA Approval for Amantadine Hydrochloride Capsules USFDA Approval for Amantadine Hydrochloride Capsules PDF 49.7 KB
07 June 2017 Strides Shasun SE Intimation Update on Credit Rating Strides Shasun SE Intimation Update on Credit Rating PDF 26.7 KB
01 June 2017 USFDA Approval For Ibuprofen Tablets USFDA Approval  For Ibuprofen Tablets PDF 54.6 KB
29 May 2017 Completion of USFDA inspection at Bangalore Facility Completion of USFDA inspection at Bangalore Facility PDF 31.7 KB
26 May 2017 Strides Shasun Declaration Pursuant to Reg 33 of SEBI LODR Strides Shasun Declaration Pursuant to Reg 33 of SEBI LODR PDF 47.5 KB
24 May 2017 USFDA Approval for Memantine Tablets USFDA Approval for Memantine Tablets PDF 50.1 KB
18 May 2017 Auditors appointment Auditors appointment PDF 82.1 KB
18 May 2017 SE Intimation Grant of Options SE Intimation Grant of Options PDF 40.4 KB
18 May 2017 Strides Shasun Board Reconstitution Strides Shasun Board Reconstitution PDF 191 KB
18 May 2017 Strides Shasun Vivimed JV 18 May 2017 Strides Shasun Vivimed JV 18 May 2017 PDF 147 KB
18 May 2017 SSL - Consol FY 17 Financials SSL - Consol FY 17 Financials PDF 218 KB
18 May 2017 SSL - Standalone FY 17 Financials SSL - Standalone FY 17 Financials PDF 153 KB
18 May 2017 Press Release – FY 17 Press Release – FY 17 PDF 208 KB
17 May 2017 SSL Earnings Call Intimation SSL Earnings Call Intimation PDF 47.1 KB
11 May 2017 Strides Shasun announcement of Board Meeting Strides Shasun announcement of Board Meeting PDF 42.8 KB
05 May 2017 Successful completion of third consecutive US FDA inspection with ‘Zero 483 Status’ over the last month 5 May 2017 Successful completion of third consecutive US FDA inspection with ‘Zero 483 Status’ over the last month 5 May 2017 PDF 66.8 KB
04 May 2017 Strides Shasun SE Intimation Strides Shasun SE Intimation PDF 40.2 KB
28 Apr 2017 Strides Shasun SE Announcement Strides Shasun SE Announcement PDF 267 KB
24 Apr 2017 Strides Shasun SE Intimation Strides Shasun SE Intimation PDF 39.1 KB
06 Apr 2017 Strides Shasun SE Intimation Dowmload PDF PDF 38.9 KB
31 Mar 2017 Shareholding pattern 31 st March 2017 Shareholding pattern PDF 804 KB
27 Mar 2017 Strides Shasun SE Claratification Strides Shasun SE Claratification PDF 44.4 KB
22 Mar 2017 Scrutinizer Report_Capping of Strides’ investment in Stelis Scrutinizer Report_Capping of Strides’ investment in Stelis PDF 545 KB
20 Mar 17 Outcome of Board Meeting De-merger of Commodity API biz Outcome of Board Meeting De-merger of Commodity API biz PDF 184 KB
28 Feb 17 Postal ballot newspaper advertisment Postal ballot newspaper advertisment PDF 886 KB
21 Feb 17 Intimation of Postal Ballot & E-Voting Intimation of Postal Ballot and E-Voting PDF 892 KB
03 Feb 17 SSL Press Release Corporate Actions SSL Press Release Corporate Actions PDF 95.2 KB
03 Feb 17 SSL Standalone Q3 FY17 Financials SSL Standalone Q3 FY17 Financials PDF 56.4 KB
03 Feb 17 SSL Consol Q3 FY17 Financials SSL Consol Q3 FY17 Financials PDF 90.8 KB
03 Feb 17 Press Release Q3 FY 2017 Press Release Q3 FY 2017 PDF 191 KB
03 Feb 17 Intimation of change in Company Secretary Intimation of change in Company Secretary PDF 39.4 KB
02 Feb 17 Fingolimod Capsules-Tentatively Approved Fingolimod Capsules-Tentatively Approved PDF 53.3 KB
02 Feb 17 Earnings Call Intimation Earnings Call Intimation PDF 40.4 KB
01 Feb 17 Clarification on TOI report Clarification on TOI report PDF 44.3 KB
25 Jan 17 Strides Shasun announcement of Board Meeting Strides Shasun announcement of Board Meeting PDF 41.5 KB
Date Title   Report

31 Dec 16 SSL Shareholding Pattern PDF 732 KB
09 Dec 16 Strides Shasun Perrigo Press Release PDF 57 KB
25 Nov 16 Strides Shasun Press Release PDF 65 KB
03 Nov 16 Stock Exchange Intimation – Mylan settlement PDF 90 KB
28 Oct 16 Intimation of designation of Group CEO as Key Managerial Personnel PDF 36 KB
28 Oct 16 Intimation on Allotment of Equity Shares to Employees on exercise of ESO PDF 37 KB
28 Oct 16 Intimation on Dividend Policy PDF 35 KB
28 Oct 16 Intimation on Grant of Options under Strides Arcolab ESOP 2015 PDF 37 KB
28 Oct 16 SSL_Standalone Q2 FY17 Financials PDF 115 KB
28 Oct 16 SSL_Consol Q2 FY17 Financials PDF 93 KB
28 Oct 16 Press Release - Q2 FY17 PDF 189 KB
21 Oct 16 Strides Shasun Announcement of Board Meeting PDF 39 KB
30 Sep 16 SSL Shareholding Pattern PDF 672 KB
25 Aug 16 Strides Shasun receives USFDA Approval for Polyethylene Glycol 3350, Powder for Solution (OTC) PDF 61 KB
24 Aug 16 Strides Shasun receives USFDA Approval for Ranitidine Tablets PDF 55 KB
17 Aug 16 Generic Partners Holdings, Australia – transaction achieved closure PDF 122 KB
17 Aug 16 Press Release - Q1 FY17 PDF 170 KB
29 Jul 16 Report of Scrutinizer AGM PDF 210 KB
30 Jun 16 Shareholding pattern PDF 909 KB
30 Jun 16 Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore PDF 54 KB
28 Jun 16 Scrutinizer’s Report - Divestment of CRAMS Business PDF 495 KB
07 Jun 16 EIR from US FDA for Oral Dosage Facility, Bangalore PDF 28 KB
07 Jun 16 Universal Corporation, Kenya – transaction achieved closure PDF 24 KB
01 Jun 16 Strides Shasun receives USFDA Tentative Approval for Roflumilast Tablets PDF 53 KB
27 May 16 Strides Shasun receives USFDA Approval for Metronidazole Tablets PDF 55 KB
26 May 16 Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet PDF 52 KB
16 May 16 Press Release - Q4 FY16 and FY16 PDF 118 KB
16 May 16 Results presentation - Q4 FY16 and FY16 PDF 1.87 MB
16 May 16 SE Intimation - Pharmacy Alliance PDF 252 KB
16 May 16 SE Intimation - Divestment of Shasun Pharma Solutions Ltd, UK (CRAMS API Biz.) PDF 284 KB
10 May 16 Strides Shasun Announcement of Board Meeting PDF 29 KB
27 Apr 16 Update on “Acquisition of controlling stake in Universal Corporation, Kenya Receipt of approval from Competition Authority of Kenya" PDF 30 KB
26 Apr 16 Strides Shasun SE Claratification PDF 29 KB
22 Apr 16 Outcome of Postal Ballot - Approval of ESOP 2016 PDF 951 KB
06 Apr 16 SE Clarification - Economic Times article PDF 29 KB
04 Apr 16 Update on Moberg Pharma – transaction achieved closure PDF 26 KB
31 Mar 16 Strides Shareholding Pattern PDF 698 KB
21 Mar 16 SE Intimation on Postal Ballot & Evoting PDF 1.30 MB
21 Mar 16 SE Intimation on Postal Ballot & Evoting PDF 1.30 MB
07 Mar 16 Allotment of Equity Shares to Employees on exercise of ESOPs PDF 29 KB
07 Mar 16 Strides Shasun to acquire 3 brands from Moberg Pharma for USD 10 Million PDF 70 KB
23 Feb 16 Update on GMS Holdings strategic investment in Stelis Biopharma PDF 28 KB
08 Feb 16 Acquisition of Generic Partners Holdings PDF 72 KB
08 Feb 16 Acquisition of Universal Corporation, Kenya PDF 60 KB
08 Feb 16 Press Release Q3 FY16 8 Feb 2016 PDF 175 KB
08 Feb 16 SSL Consol Q3 FY 2016 Financials PDF 87 KB
08 Feb 16 SSL_Standalone Q3 FY 2016 Financials PDF 67 KB
08 Feb 16 Appointment of Mr. Shashank Sinha as CEO PDF 36 KB
03 Feb 16 Acquisition of seven brands from Johnson & Johnson - transaction achieved closure PDF 34 KB
01 Feb 16 Acquisition of CNS divisions of erstwhile Ranbaxy - transaction achieved closure PDF 52 KB
27 Jan 16 CCI approval_Johnson & Johnson PDF 25 KB
22 Jan 16 Update on “Acquisition of CNS division of erstwhile Ranbaxy” PDF 143 KB
20 Jan 16 Shareholding Pattern - 31 December 2015 PDF 808 KB
19 Jan 16 Clarification on Business Standard article PDF 35 KB
Date Title   Report

21 Dec 15 Strides Shasun receives approval from Drug Controller General of India for generic version of Sofosbuvir PDF 70.4 KB
17 Dec 15 Strides Shasun Letter to StockExchange Dec 17 2015 PDF 35.3 KB
14 Dec 15 Strides Shasun EGM-Coverpage PDF 28.7 KB
11 Dec 15 Strides Arcolab letter PDF 474 KB
12 Dec 15 Annexure 1 Outcome & Voting Results of EGM as per Reg 44(3) PDF 1.23 MB
12 Dec 15 Annexure 2 Scrutinizer Combined Report-On poll and e-voting PDF 130 KB
16 Dec 15 Strides Shasun Response to Biz Standard Article-16 Dec 2015 PDF 21.7 KB
15 Dec 15 Strides Response to NSE 15 Dec 2015 PDF 75.3 KB
15 Dec 15 Strides Response to BSE 15 Dec 2015 PDF 62.5 B
23 Nov 15 strides Shasun Stock Exchange Intimation PDF 45 KB
20 Nov 15 Strides Shasun - Intimation of EGM PDF 1.80 MB
20 Nov 15 Strides Shasun - Allotment PDF 55 KB
19 Nov 15 Strides Arcolab_Name change letter PDF 51 KB
05 Nov 15 Strides Arcolab_Intimation to Stock Exchange PDF 56 KB
29 Oct 15 FIPB Approval Intimation to Stock Exchange PDF 100 KB
27 Oct 15 Press Release Q2 FY16 INR PDF 154 KB
27 Oct 15 Consol SEBI Q2 2015-16 PDF 91 KB
27 Oct 15 Standalone SEBI Q2 2015-16 PDF 74 KB
06 Oct 15 Intimation of Postal Ballot PDF 1.36 MB
28 Sept 15 Intimation to SE_Fund Raising PDF 47 KB
19 Sept 15 Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy PDF 92 KB
16 Sept 15 Update on Scheme of Amalgamation of Shasun and Strides PDF 48 KB
31 Aug 15 Update on ‘Acquisition of a generic pharmaceutical business in Australia PDF 44 KB
31 July 15 Strides Arcolab receives ANDA approval from US FDA for Benzonatate Softgel Capsules PDF 124 KB
30 July 15 SAL - Consolidated financial statements PDF 78 KB
30 July 15 SEBI Standalone PDF 78 KB
30 July 15 Strides Arcolab announces Q1 FY16 Results PDF 492 KB
10 July 15 Strides arcolab scrutinizer's report PDF 560 KB
10 July 15 Strides arcolab combined result clause 35 format PDF 120 KB
10 July 15 Strides arcolab outcome of postal ballot cover note PDF 138 KB
19 June 15 Strides Intimation PDF 53 KB
17 June 15 Strides Arcolab Update on Scheme of Amalgamation PDF 50 KB
22 May 15 Strides Arcolab announces Q4 FY15 and FY15 Results PDF 535 KB
21 May 15 Strides inks agreements to acquire a generic pharmaceutical business in Australia and related assets from Aspen for approximately A$380 million
Acquisition to be EPS accretive immediately
PDF 82.2 KB
15 May 15 Strides Arcolab receives ANDA approval from US FDA for Lamivudine and Zidovudine Tablets PDF 63.8 KB
15 April 15 Strides Arcolab receives ANDA approval from US FDA for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution. PDF 79 KB
27 Feb 15 Launch of generic drug Sofosbuvir in India under the brand name 'Virso' PDF 56.8 KB
02 Feb 15 Statement Of Standalone Unaudited Results For The Nine Months Ended December 31, 2014. PDF 67 KB
02 Feb 15 Strides Arcolab reports Q3 FY 2014-15 Results Pharma Revenues at INR 3,261 Mn with an EBITDA of INR 664 Mn EBITDA Margin at 20%. PDF 127 KB
20 Jan 15 Strides Arcolab signs Agreement with Gilead Sciences to Manufacture and Distribute Tenofovir Alafenamide (TAF) based HIV treatments in 112 Developing Countries. PDF 57 KB
13 Jan 15 Singapores Economic Development Board grants International Headquarter Status to Strides Pharma Global Pte. Ltd. Singapore. PDF 82 KB
Date Title   Report

16 Dec 14 Strides Arcolab receives US FDA approval for Calcitriol Softgel Capsules. PDF 65 KB
03 Dec 14 Stelis Biopharma Begins Construction of Multi-Product Biologics Facility At Bioxcell Biotechnology Park, Johor, Malaysia. PDF 210 KB
27 Nov 14 Strides Arcolab Press Release MMV announces collaborations with Cipla and Strides. PDF 72 KB
20 Nov 14 Appointment of Mr. Abhaya Kumar PDF 43 KB
07 Nov 14 Strides Arcolab reports Robust Q2 FY 2014-15 Results. PDF 126 KB
01 Oct 14 Strides Arcolab clarifies on the Import Alert published on the US FDA website regarding its subsidiary Beltapharm SpA, Italy. PDF 58 KB
29 Sept 14 Strides Arcolab announces strategic Investor for its greenfield Biotech project. PDF 87 KB
29 Sept 14 Strides Arcolab and Shasun Pharmaceuticals combine to accelerate strategy and growth. PDF 142 KB
15 Sept 14 Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. PDF 88 KB
26 Aug 14 Strides Arcolab receives US FDA approval for Buspirone Tablets. PDF 92 KB
25 Jul 14 Strides Arcolab announces Q1 FY 2014-15 Results. PDF 73 KB
23 Jul 14 Strides Arcolab receives USFDA approval for Tacrolimus Capsules. PDF 92 KB
21 Jul 14 Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. PDF 82 KB
16 Jul 14 Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. PDF 210 KB
25 Jun 14 Strides Arcolab receives US FDA approval for Imiquimod Cream. PDF 77 KB
06 Jun 14 Strides Arcolab receives US FDA approval for Methoxsalen Softgel Capsules. PDF 78 KB
23 May 14 Strides financial results for the Quarter ending March 31, 2014 and Financial Year ending March 31, 2014. PDF 81 KB
25 Apr 14 Strides reports continued US FDA approval Status for Oral Dosage Facility. PDF 76 KB
Date Title   Report

10 Dec 13 Update on Agila Transaction. PDF 107 KB
5 Dec 13 Strides Arcolab completes sale of Agila Specialties division to Mylan. PDF 113 KB
14 Nov 13 Strides Arcolab announces Q3'13 Results. PDF 84 KB
23 Oct 13 Stelis Biopharma signs a Research Collaboration Agreement with Bio-Scaffold International Pte Ltd to develop scaffolds loaded with BMP and stem cells for various medical applications. PDF 124 KB
18 Sep 13 Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. PDF 75 KB
1 Aug 13 Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablets. PDF 76 KB
25 Jul 13 Global Pharma business in line with Guidance. PDF 81 KB
25 Jun 13 Strides announces WHO pre-qualification for Artemether+Lumifantrine (AL). PDF 68 KB
25 Apr 13 Strides reports strong quarterly performance - Standalone Financial Highlights. PDF 80 KB
16 Apr 13 Pfenex Inc. and Agila Biotech Private Limited Announce Joint Venture to Develop Biosimilar Products for the Global Market. PDF 85 KB
19 Mar 13 Malaysian Bio-Xcell SDN BHD seals a deal exceeding US$35M (~RM107M) with AGILA Biotech SDN BHD during Biopharma Asia 2013. PDF 98 KB
06 Mar 13 Agila Receives Us FDA approval for Zoledronic Acid Injection. PDF 86 KB
28 Feb 13 Strides Arcolab to Sell AGILA Specialties Division to Mylan INC. For An Aggregate Sum of US$1,600 Million in Cash and Potential Additional Consideration Of Up To US$250 Million. PDF 355 KB
28 Feb 13 Strides reports Continued Strong Operational Performance. PDF 147 KB
Date Title   Report

05 Dec 12 Strides Arcolab and Lilly Enter Strategic Partnership to Deliver High-Quality, Branded Generic Cancer Medicines for Emerging Markets. PDF 90 KB
19 Oct 12 Strides reports Continued Strong Operational Performance in Q3'12. PDF 93 KB
18 Oct 12 Strides Arcolab Receives 2 More Approvals For Oncology Products from USFDA. PDF 84 KB
13 Sep 12 Strides Arcolab Announces US FDA Approval of Its Polish Sterile Injectable Facility. PDF 81 KB
03 Sep 12 Strides Arcolab Receives US FDA Approval For Vinorelbine Injection. PDF 86 KB
29 Aug 12 Strides Arcolab Receives US FDA Approval For Topotecan Injection. PDF 86 KB
8 Aug 12 Strides Arcolab Receives Us FDA Approval For Oxaliplatin Injection. PDF 87 KB
6 Aug 12 Strides collaborates with Gilead Sciences. PDF 67 KB
27 Jul 12 Strides reports Strong Operational Performance in Q2'12. PDF 133 KB
24 Jul 12 Proparco Investment in Strides' African Arm. PDF 67 KB
20 Jul 12 Strides Arcolab Receives US FDA Approval For Fluorouracil Injection. PDF 77 KB
27 Jun 12 Strides redeems FCCBs due 2012 Net Debt / Equity at 0.75. PDF 100 KB
11 Jul 12 Agila Announces Entry Into Canadian Injectable Market. PDF 79 KB
27 Jun 12 Strides redeems FCCBs due 2012 Net Debt / Equity at 0.75. PDF 100 KB
10 May 12 Strides Arcolab Receives US FDA Approval for Acetazolamide Injection, USP. PDF 89 KB
26 Apr 12 Strides delivers Robust Q1'12 Performance. PDF 133 KB
26 Apr 12 Strides acquires US FDA approved Sterile Formulations facility. PDF 76 KB
19 Apr 12 Strides Arcolab Receives US FDA Approval Forcisplatin Injection. PDF 85 KB
11 Apr 12 Strides Arcolab Receives US FDA Nod For Vancomycin Oral Capsules. PDF 77 KB
3 Apr 12 Strides Arcolab Announces Health Canada Approval for Tobramycin Injection. PDF 77 KB
30 Mar 12 Strides Arcolab Receives US FDA Approval For Methotrexate Injection. PDF 84 KB
27 Feb 12 Audited Financial Results Year Ended December 31, 2011. PDF 152 KB
24 Feb 12 Strides Arcolab Announces Us FDA Approval For Its 'Brazilian Sterile Penems Facility'. PDF 93.2 KB
24 Jan 12 Sale of generic pharmaceutical operations in Australia and Southeast Asia for AU$375 million - Analyst Presentation PDF 1.33 MB
24 Jan 12 Strides Arcolab Sells Its Generic Pharmaceutical Operations In Australia and Southeast Asia to Watson Pharmaceuticals for Au$ 375 Million. PDF 79 KB
Date Title   Report

22 Dec 11 Strides Press Release Sterile Plant Approval and Fludarabine Approval. PDF 104 KB
15 Dec 11 Strides Press Release Cytarabine Approval. PDF 99 KB
24 Nov 11 Approval Momentum for Oncology Products Continues With Two More USFDA Approvals. PDF 106 KB
11 Nov 11 Strides Arcolab receives US FDA approval for Carboplatin Injection. PDF 178 KB
02 Nov 11 Strides Arcolab Receives US FDA Approval for Doxorubicin Injection. PDF 87 KB
24 Oct 11 Strides Results Pack Financials for Q3 '11. PDF 974 KB
24 Oct 11 Strides delivers Superior Q3 '2011 Financials Ups Full Year Guidance PDF 125 KB
20 Oct 11 Strides Arcolab Receives US FDA Approval For Bupivacaine Hydrochloride Injection, USP PDF 77 KB
10 Oct 11 Strides Arcolab Receives US FDA Approval for Cladribine Injection PDF 77 KB
03 Oct 11 Strides Arcolab Receives US FDA Approval For Clindamycin Injection, USP PDF 74 KB
30 Sep 11 Strides Oncology Approvals Gain Momentum With Two More USFDA Approvals PDF 88 KB
15 Sep 11 Strides Announces European Approval For Oxaliplatin Injection PDF 90 KB
14 Sep 11 Strides continued US FDA Approval Status For Oral Dosage Facility PDF 66 KB
28 July 11 Strides Arcolab Announces US FDA Approval For Acarbose Tablets PDF 106 KB
26 July 11 Strides Arcolab Announces US FDA Approval For Gemcitabine For Injection USP PDF 77 KB
1 July 11 Strides Announces European Approval For Its Oral Dosage Facility In Its Oncology Complex PDF 50 KB
1 July 11 Strides Arcolab Receives US FDA Approval For Polymyxin Injection PDF 50 KB
29 Jun 11 Strides Arcolab Joins The Malaysian BIO-XCELL Ecosystem PDF 50 KB
21 Jun 11 Strides Arcolab Receives US ADA Approval For Levofloxacin Injection PDF 50 KB
5 May 11 Strides Arcolab Receives US FDA Approval For Midazolam Injection Multi-Dose Vials PDF 50 KB
2 May 11 Strides announces US FDA approval for its Oncology facility in Bangalore PDF 50 KB
25 Apr 11 Results Pack Financials for Q1 2011 PDF 50 KB
25 Apr 11 Strides Announces Q1 ‘2011 Financial Results PDF 50 KB
18 Apr 11 Strides Arcolab Announces US FDA Approval For Its ‘New Sterile Injectable Facility PDF 50 KB
13 Apr 11 Strides Arcolab Receives US FDA Nod To Commercialize First Liquid Injectable Product From Its New Facility PDF 50 KB
4 Mar 11 Strides Announces First European Approval For Oncology Product PDF 50 KB
1 Mar 11 Strides arcolab receives US FDA nod to commercialize first sterile product from new facility PDF 50 KB
24 Feb 11 Results Pack Financials for the year 2010 PDF 50 KB
24 Feb 11 Press Release PDF 50 KB
20 Jan 11 AGILA Signs Agreement with Biochimico To Set Up A Joint Venture Company In Brazil. PDF 50 KB
18 Jan 11 Strides Arcolab announces US FDA Approval for additional Adenosine Injection USP PDF 50 KB
Date Title   Report

10 Dec 10 Strides Arcolab Announces US FDA Approval for Lidocaine Hydrochloride Injection. PDF 50 KB
09 Dec 10 Strides acquires controlling stake in Inbiopro. PDF 50 KB
01 Dec 10 Strides Arcolab Announces US FDA Approval Of Midazolam Hydrochloride Injection. PDF 50 KB
25 Nov 10 Strides Specialties Rebranded As Agila Specialties. PDF 50 KB
29 Oct 10 Strides Arcolab receives ANDA approval from US FDA for Lamivudine and Zidovudine under PEPFAR scheme. DF 50 KB
27 Oct 10 Strong Performance Across Business Divisions Steers 35% Growth In Revenue For Strides. PDF 50 KB
26 Oct 10 Strides' Generic Oseltamivir Receives WHO Prequalification for treatment of H1N1. PDF 50 KB
04 Oct 10 Strides Arcolab Records 50th Anda Approval 2 More Anda Approvals Received. PDF 50 KB
04 Aug 10 Strides Arcolab announces US FDA approval for Ergocalciferol Capsules 1.25mg first approval for a Soft Gelatine Product. PDF 50 KB
03 Aug 10 Strides' Sterile Carbapenems Facility In Campos, Brazil receives MHRA Approval. PDF 50 KB
30 Jul 10 Strides Arcolab Announces US FDA Approval of Sumatriptan Succinate Injection. PDF 50 KB
30 Jul 10 Strides Arcolab Announces US FDA Approval of Rocuronium Bromide Injection. PDF 50 KB
27 Jul 10 Strides today announced Q2-10 results. DF 50 KB
13 Jul 10 Strides Annual Report 2009 Wins LACP Platinum Award. PDF 50 KB
18 May 10 Strides Arcolab Receives ANDA approval from US FDA for Abacavir Sulfate Tablets, 300mg under PEPFAR Scheme. PDF 50 KB
14 May 10 Strides and Pfizer Strengthen Partnership. PDF 50 KB
13 May 10 Strides Arcolab announces US FDA Approval of Vecuronium Bromide for Injection. PDF 50 KB
12 May 10 Strides Arcolab announces US FDA Approval Of Bacitracin For Injection, USP. PDF 50 KB
11 May 10 Manish Gupta to lead Pharma Business at Strides Arcolab. Manish Gupta to lead Pharma Business at Strides Arcolab PDF 50 KB
22 Apr 10 Strides Arcolab Announces US FDA Tentative Approval Of Additional Adenosine Injection. Strides Arcolab Announces US FDA Tentative Approval Of Additional Adenosine Injection PDF 50 KB
22 Apr 10 Strides today announced Q1'10 financials. PDF 50 KB
21 Apr 10 Strides Arcolab Announces US FDA Approval For Metoprolol Tartrate Injection. Strides Arcolab Announces US FDA Approval For Metoprolol Tartrate Injection PDF 50 KB
20 Apr 10 Strides redeems USD 34 Million FCCBs due 2010. Strides redeems USD 34 Million FCCBs due 2010 PDF 50 KB
19 Apr 10 Strides Arcolab Announces US FDA Approval For Mesna Injection. Strides Arcolab Announces US FDA Approval For Mesna Injection PDF 50 KB
14 Apr 10 Strides Arcolab Announces US FDA Approval For Granisetron Hydrochloride Injection. Strides Arcolab Announces US FDA Approval For Granisetron Hydrochloride Injection PDF 50 KB
18 Mar 10 Strides revises guidance upwards for FY 2010. PDF 50 KB
18 Mar 10 Strides and Aspen restructure Oncology arrangements. Strides and Aspen restructure Oncology arrangements PDF 50 KB
04 Mar 10 Strides to acquire Campos facility in Brazil from Aspen. Strides to acquire Campos facility in Brazil from Aspen PDF 50 KB
24 Feb 10 Results Pack Financials for the year 2009. Results Pack Financials for the year 2009 PDF 50 KB
24 Feb 10 Audited Financial Results for the Year ended 31 December 2009. Audited Financial Results for the Year ended 31 December 2009 PDF 50 KB
09 Feb 10 Strides Arcolab announces US FDA approval for Labetalol Hydrochloride injection, USP – total Approvals in sterile space at 18. Strides Arcolab announces US FDA approval for Labetalol Hydrochloride injection, USP – total Approvals in sterile space at 18 PDF 50 KB
20 Jan 10 Strides Arcolab appoints Venkat Iyer To Board of Directors. Strides Arcolab appoints Venkat Iyer To Board of Directors PDF 54 KB
6 Jan 10 Pfizer and Strides Arcolab to Collaborate on Generic Products. Pfizer and Strides Arcolab to Collaborate on Generic Products. PDF 74 KB

Earnings Call Transcript

Date Title Report
09 Feb 18 Earnings call transcript for Q3 FY18. PDF 109 KB
31 Oct 17 Earnings call transcript for Q2 FY18. PDF 111 KB
11 Aug 17 Earnings call transcript for Q1 FY18. PDF 102 KB
18 May 17 Earnings call transcript for Q4 FY17 PDF 156 KB
Date Title Report
03 Feb 17 Earnings call transcript for Q3 FY17 PDF 177 KB
28 Oct 16 Earnings call transcript for Q2 FY17 PDF 155 KB
17 Aug 16 Earnings call transcript for Q1 FY17 PDF 126 KB
16 May 16 Earnings call transcript for Q4 FY 16 PDF 136 KB
Date Title Report
08 Feb 16 Earnings Call transcript for Q3 FY 16 PDF 124 KB
27 Oct 15 Earnings call transcript for Q2 FY 2016 PDF 92 KB
30 Jul 15 Strides Arcolab Limited's 1QFY16 Earnings Conference Call. PDF 129 KB
Date Title Report
02 Feb 15 Strides Arcolab Limited's Q3 FY15 Earnings Conference Call. PDF 103 KB
07 Nov 14 Strides Arcolabs Earnings Call Q2 FY 2014-15. PDF 201 KB
25 Jul 14 Strides Arcolab Earnings Call Transcript Q1 FY 2014-15. PDF 119 KB
23 May 14 Strides Arcolab Earnings Call (Q5 & 15 Month Period Ended March 2014). PDF 120 KB
Date Title Report
07 Feb 14 Strides Arcolab Limited's Q4 CY13 Earnings Conference Call. PDF 162 KB
10 Dec 13 Strides Arcolab Limited Conference Call. PDF 91 KB
25 Jul 13 Strides Arcolab Limited Q2 CY13 Earnings Conference Call PDF 87 KB
28 Feb 13 Strides Arcolab Discuss the Transaction of Sale of Agila Specialties Division to Mylan & Q4 CY12 Results -- Conference Call. PDF 128 KB
Date Title Report
24 Jan 12 "Strides Arcolab – Analyst Call" PDF 78 KB
27 Feb 12 "Strides Acrolabs CY11 Post Results Conference Call" PDF 92 KB
26 Apr 12 "Strides Arcolab Q1 CY12 Conference Call" . PDF 114 KB
27 Jul 12 Strides Arcolab Q2CY12 Post Results Conference Call PDF 102 KB
19 Oct 12 "Strides Arcolab Limited Q3 and CY12 Results Conference Call" PDF 118 KB
Date Title Report
25 Feb 11 "Strides Arcolab's CY2010 Post Results Conference Call" PDF 92 KB
25 Apr 11 "Strides Arcolab Limited Q1 CY11 Results Conference Call" PDF 103 KB
27 Jul 11 "Strides Arcolab Limited Conference Call" PDF 106 KB
24 Oct 11 "Strides Arcolab Results Earnings Conference Call" PDF 115 KB
Date Title Report
28 Oct 10 "Strides Arcolab's Q3 CY10 Post Results Conference Call" PDF 50 KB